Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share
Portfolio Pulse from
Keros Therapeutics' stock has dropped significantly due to safety concerns in its Phase 2 TROPOS trial, but it is now trading at cash value. The company has a cash runway until Q4 2028, supported by a $200 million payment from Takeda, with potential for future milestone payments.
December 18, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics' stock has dropped due to safety concerns in its Phase 2 TROPOS trial, but it is now trading at cash value. The company has a cash runway until Q4 2028, supported by a $200 million payment from Takeda, with potential for future milestone payments.
The stock's drop due to safety concerns presents a risk, but the current trading at cash value and the financial backing from Takeda provide a strong foundation for potential recovery. The extended cash runway and potential milestone payments further enhance the upside potential.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100